Anixa Biosciences, Inc. (ANIX) is a publicly traded Healthcare sector company. As of May 21, 2026, ANIX trades at $2.79 with a market cap of $92.54M and a P/E ratio of -8.04. ANIX moved +3.18% today. Year to date, ANIX is -14.15%; over the trailing twelve months it is +4.60%. Its 52-week range spans $2.07 to $5.46. Analyst consensus is buy with an average price target of $14.00. Rallies surfaces ANIX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Anixa Biosciences’ CAR-T Patients Survive up to 28 Months in Phase 1 Trial: Anixa Biosciences reported that in its Phase 1 lira-cel ovarian cancer CAR-T trial, one patient survived 28 months and three others 17–18 months versus a median expectancy of 3–4 months, while four additional participants reached 11, 11, 8 and 7 months. No dose-limiting toxicities, ICANS or significant CRS occurred.
| Metric | Value |
|---|---|
| Price | $2.79 |
| Market Cap | $92.54M |
| P/E Ratio | -8.04 |
| EPS | $-0.34 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.46 |
| 52-Week Low | $2.07 |
| Volume | 34 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-11.03M |
| Gross Margin | 0.00% |
1 analysts cover ANIX: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $14.00.